HK inno.N reveals differentiated clinical results for K-CAB

South Korean bio-health company HK inno.N has been expanding its market by steadily announcing differentiated clinical results for its gastroesophageal reflux disease (GERD) drug K-CAB.

K-CAB, expected to exceed 100 billion won ($76.2 million) in sales this year, is a blockbuster drug for HK inno.N.

K-CAB was originally developed in the form of an oral pill. It is divided into K-CAB tablets for general oral administration and K-CAB orally disintegrating tablets that can be taken without water.

At the Korean Society for Clinical Pharmacology and Therapeutics held last month, clinical results were announced, demonstrating that K-CAB orally disintegrating tablets, when administered through the sublingual route, are pharmacokinetically equivalent to oral administration.

This suggests that it could be a new alternative for patients, such as those in intensive care units, where oral administration is not feasible.

It was also shown that kidney transplant patients can safely take K-CAB.

Prof. Jang-hee Cho of Kyungpook National University Hospital presented clinical results at the American Society of Nephrology (ASN) last month, stating that kidney transplant patients can take K-CAB tablets and immunosuppressants together without affecting the blood concentration of immunosuppressants.

Patients taking both drugs showed no signs of immune rejection, and kidney function remained intact.

HK inno.N is consistently conducting clinical trials to expand the target population for K-CAB. Currently, there are about 80 ongoing or completed clinical studies on K-CAB, with approximately 50 published clinical papers.

Write to Young-ae Lee at 0ae@hankyung.com